

Special Issue

Feature Reviews in Precision Oncology

Message from the Guest Editor

The Special Issue aims to gather authoritative reviews that cover a broad spectrum of topics within precision oncology, including, but not limited to, the following:

- Advances in genomic and molecular profiling;
- Targeted therapies and immunotherapies;
- Molecular imaging and theranostics;
- Biomarker discovery and validation;
- Personalized treatment strategies;
- Emerging technologies and methodologies in cancer research.

Your expertise and insights would be a valuable addition to this collection. We encourage you to submit a review article that addresses key developments, current trends, and future directions in your area of research. Please note that this Special Issue will only accept review articles, not original research papers. We look forward to your contribution and to shaping a comprehensive resource that will serve the precision oncology community.

Guest Editor

Dr. Luca Filippi

Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Viale Oxfors 81, 00133 Rome, Italy

Deadline for manuscript submissions

28 February 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/214828

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).